iBio
IBIO
28 hedge funds and large institutions have $696K invested in iBio in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.
41% more call options, than puts
Call options by funds: $262K | Put options by funds: $186K
0.33% less ownership
Funds ownership: 0.67% → 0.34% (-0.33%)
3% less funds holding
Funds holding: 29 → 28 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
80% less capital invested
Capital invested by funds: $3.45M → $696K (-$2.75M)
Top Buyers
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$146K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$15K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.8K |
| 4 |
Morgan Stanley
New York
|
+$4.83K |
| 5 |
RG
Retirement Group
San Diego,
California
|
+$264 |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$1.09M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$153K |
| 3 |
VF
Virtu Financial
New York
|
-$95K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$52K |
| 5 |
Renaissance Technologies
New York
|
-$20.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAP
26
Arax Advisory Partners
Denver,
Colorado
| $22 | – | – | – |
|
|
WWP
27
WR Wealth Planners
Columbia,
Missouri
| $5 | – | – | – |
|
|
AC
28
Armistice Capital
New York
| – | -$1.09M | -26,282 | Closed |
|
|
29
Dimensional Fund Advisors
Austin,
Texas
| – | -$153K | -3,680 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$95K | -2,294 | Closed |
|
|
BCM
31
Bridgeway Capital Management
Houston,
Texas
| – | -$52K | -1,250 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.7K | -90 | -74% |
|
|
BAM
33
Belpointe Asset Management
Reno,
Nevada
| – | -$1.71K | -41 | Closed |
|
IBIO Hedge Fund Activity: Q2 2023 in Review
28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2023, worth a combined $696K — down 80% from $3.45M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IBIO and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Avantax Planning Partners, opening a new position worth an estimated $146K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.09M sold.
- 28 institutional investors held iBio (IBIO) as of Q2 2023, down from 29 in Q1 2023.
- Funds reported $696K of iBio stock for Q2 2023, down 80% quarter-over-quarter.
- 5 funds opened new iBio positions in Q2 2023 and 6 closed out, a net change of -1 holder.
- The largest iBio buyer in Q2 2023 was Avantax Planning Partners, an estimated $146K added.
- The largest iBio seller in Q2 2023 was Armistice Capital, an estimated $1.09M sold.
Based on aggregated 13F filings for Q2 2023.